Parallax Health Sciences, Inc. PRLX OTC

Parallax Health Sciences, Inc. (PRLX) has shown exceptional revenue growth over the past 3 years, expanding from $23M to $128,600 (average +269.9%/yr). The company reported a net loss of $13M in its most recent fiscal year, with earnings trending at -10.1%/yr. The net profit margin is -10004.9%, which is negative. the company was profitable in 1 out of the last 4 years tracked. The gross margin is 86.9% (high), with a +69.4pp trend over the period. With a market cap data available and MOAT composite score of 50/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (58/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (25/100, Fail) — the company has frequently reported losses. Looking at the full 14-year history, the company was profitable in 1 of 14 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (50/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 29/100 with 0/5 criteria passed.